Physician profile
Brandy Hughes
NPI 1194059162
$28,919.40
in general payments reported to CMS, 2019-2025
57 companies · $3,022 in 2025
The $3,022 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $5,788 · 2023: $3,273 · 2024: $3,225 · 2025: $3,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,520.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,703.71 | 2021-2025 | |
| Allergan, INC. | $1,412.62 | 2021-2022 | |
| Ucb, INC. | $901.74 | 2021-2025 | Briviact, Zilbrysq, Rystiggo |
| Lundbeck LLC | $825.38 | 2021-2025 | Vyepti |
| Pfizer INC. | $789.32 | 2022-2025 | |
| Biogen, INC. | $722.09 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $589.59 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $485.98 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $476.16 | 2022 | |
| Neurelis, INC. | $468.86 | 2021-2025 | Valtoco |
| Amgen INC. | $455.28 | 2021-2025 | Aimovig, Uplizna |
| Novartis Pharmaceuticals Corporation | $401.75 | 2021-2025 | |
| Sk Life Science, INC. | $358.25 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $345.24 | 2021 | |
| Impel Pharmaceuticals INC. | $330.34 | 2022-2023 | Trudhesa |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.